Cowen Raises Price Target on Activision Blizzard (ATVI) Following 2Q Results

Benchmark Raises Price Target on Activision Blizzard (ATVI) to $32.53 Following EPS Beat

Benchmark reiterated a Buy rating on Activision Blizzard (NASDAQ: ATVI), and raised the price target to $32.53 (from $30.78), following 2Q15 results. Sales were $759M, above both guidance at $650M and Street estimate at $667M. Adjusted EPS was $0.13 Beating guidance at $0.07 and Street estimate at $0.08.

Analyst... More

Activision Blizzard (ATVI) PT Raised to $30 at UBS

UBS analyst Eric Sheridan raised his price target on Activision Blizzard (NASDAQ: ATVI) to $30.00 (from $28.00) following solid Q2.

commented, "ATVI delivered another quarter of upside across revenues, EBITDA and EPS driven by its strongest Q2 digital revenues to date. Moreover, the Blizzard segment delivered 13% YoY... More

Sterne Agee CRT Raises Price Target on Activision Blizzard (ATVI) to $32 Following 5c EPS Beat

Sterne Agee CRT reiterated a Buy rating on Activision Blizzard (NASDAQ: ATVI), and raised the price target to $32.00 (from $27.00), following 2Q15 results. ATVI reported revenue and EPS of $759M and $0.13 compared to consensus estimates of $667M and $0.08 respectively. Management raised FY revenue and EPS... More

Activision Blizzard (ATVI) PT Lifted to $31 at Mizuho Securities after 'Crushing' Q2 Views

Mizuho Securities analyst Neil Doshi reiterated a Buy rating and raised his price target on Activision Blizzard (NASDAQ: ATVI) to $31.00 (from $29.00) after the company 'crushes' Q2.

Doshi commented, "This was a clean beat and raise quarter, and we are convinced that there... More

Activision Blizzard (ATVI) PT Raised to $32 at Brean Capital Amid Strong Q2

Brean Capital analyst Todd Mitchell reiterated a Buy rating and raised his price target on Activision Blizzard (NASDAQ: ATVI) to $32.00 (from $30.00) following strong result after the close. The analyst said current trends give us greater confidence in Activisions potential upside.

Mitchell commented, "Activision reported upside to 2Q15 guidance and, for the second... More

Activision Blizzard (ATVI) PT Lifted to $33 at Jefferies Amid Q2 'Beat'

Jefferies US Interactive Entertainment Team reiterated a Buy rating and raised their price target on Activision Blizzard (NASDAQ: ATVI) to $33.00 (from $26.00) following a strong beat in the quarter.

The tam commented, "It was a strong beat and raise for 'Franchise Pick' ATVI,... More

After-Hours Stock Movers 08/04: (USNA) (CHUY) (Z) Higher; (ETSY) (TRMB) (GLUU) (DIS) Lower (more...)

Etsy (NASDAQ: ETSY) 15.2% LOWER; reported Q2 EPS of ($0.07), versus ($0.08) reported last year. Revenue for the quarter came in at $61.4 million, versus $42.5 million reported last year.

USANA Health Sciences (NYSE: USNA) 14.8% HIGHER; reported Q2 EPS of $1.92, $0.32 better than the analyst estimate of $1.60. Revenue for the quarter came in at $233.2 million versus the consensus estimate of $212.94 million.

ChannelAdvisor (NYSE: ECOM) 13.4% HIGHER; reported Q2 EPS of ($0.10), $0.19 better than the analyst estimate of ($0.29).... More

Activision Blizzard (ATVI) Tops Q2 EPS by 5c, Revenue Beats, Offers Guidance

Activision Blizzard (NASDAQ: ATVI) reported Q2 EPS of $0.13, $0.05 better than the analyst estimate of $0.08. Revenue for the quarter came in at $759 million versus the consensus estimate of $665.53 million.

Activision Blizzards third quarter and calendar year 2015 outlook is, as follows:

Activision Blizzard (ATVI) halted with news pending

Activision Blizzard (NASDAQ: ATVI) halted with news pending.

Trading Radar for 8/4: Zillow (Z), Archer Daniels (ADM), Hyatt Hotels (H), Kellogg (K), Sprint (S), Mosaic (MOS) Report

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

A.M. Castle & Co. (NYSE: CAS) - consensus loss $0.48
ALLETE, Inc. (NYSE: ALE) - consensus EPS $0.50
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.54
Abiomed (Nasdaq: ABMD) - consensus EPS $0.08
Aetna (NYSE: AET) - consensus EPS $1.82
Affimed (Nasdaq: AFMD) - consensus loss $0.17
Albany... More